65,437 trials
Erectile Dysfunction
Primary: Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY2452473 — 514; 495; 453; 463 nanograms*hours per milliliter (ng*h/mL)
Uterine Fibroids
Primary: Percentage of Participants in Amenorrhea at the End of Treatment Course 1 — 0.0; 53.8; 46.7 percentage of participants — p=0.0019
Ischemia · Angina
Primary: Mean Fractional Flow Reserve (FFR) — 0.84; 0.79 ratio
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 17; 9; 3; 1 Participants
Acquired Hypogonadotropic Hypogonadism · Obesity
Primary: Change From Baseline in Lean Body Mass (LBM) at Week 48 — 65.23; 65.60; 68.12; 3.14 kg — p=0.7103
Anemia
Primary: A Composite of In-hospital Postoperative Morbidity and Mortality — 59; 68 Participants
Dorsal Hands
Primary: The Efficacy of Restylane Vital on Skin Structure Compared to no Treatment Using a Validated Scale. — 0.85; 2.17 units on a scale
Non-Hodgkin's Lymphoma
Primary: Maximum Tolerated Dose — 115 milligrams per meter squared
Influenza A Virus Infection
Primary: Clinical Status at Day 7 — 2; 2; 15; 10 Participants — p=0.54
Gastric Cancer · Pancreatic Cancer
Primary: Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection — 70; 2; 4 Participants
Irritable Bowel Syndrome Characterized by Constipation
Primary: Number of Overall Responders - ITT Population — 63; 106; 103 Participants
Intravenous Infiltration
Primary: Number of Participants With Intraveneous Infiltration of FDG During Routine PET/CT Imaging by Visually Assessment of Interpreting Physicians — 17; 32 Participants
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET — -4.57; 4.57 percentage change from baseline
Diabetes Complications · Diabetic Neuropathies
Primary: Postural Sway During Shod Standing — 4.3; 3.1 cm^2
Scabies · Head Lice
Primary: Number of Participants With Headlice — 3 Participants